1.   Bay Area biotech firms have also been on the buy side of the merger binge.

2.   Bay Area biotech firms like Gilead Sciences seized the chance to go public.

3.   Bay Area biotech firms ran more than half of all U.S. cancer-drug experiments.

4.   Bay Area firms like Tularik, Caliper and Maxygen have all soared since their fourth-quarter debuts.